The app allows users to record their symptoms, general well-being, medications and other factors.
After agreeing to unload most of its struggling vaccines unit to GlaxoSmithKline, Novartis now has just its influenza vaccines to ship off as it looks to focus on other core businesses. And new, promising data for the Swiss drug giant's H7N9 bird flu candidate could give the company a boost as it looks to lock down a buyer.
Fresh off winning European backing for broader use--which could prompt more multiple sclerosis patients to switch--Gilenya's ability to protect patients' brains is at center stage at this week's American Academy of Neurology meeting.
Despite a wave of M&A deals aimed at increasing efficiency and lowering expenses in the pharmaceutical industry, drug prices continue to rise, with several drug companies nearly doubling the costs of key products over the last 7 years. That's the conclusion of an analysis prepared for Bloomberg by DRX, a California-based provider of health software.
When Big Pharma starts talking about big buyouts, the sales and marketing departments start chattering about their jobs. Last week's Novartis-plus-GlaxoSmithKline cancer deal is one prime example. Another, bigger one: Pfizer's proposed $100 billion-or-so buyout of AstraZeneca.
After a quick march through the clinic, Novartis has won early FDA approval for the new "breakthrough" lung cancer drug ceritinib (or LDK378), which will now be launched as Zykadia.
France's Transgene took a hit this morning after the biotech announced that Novartis had decided to pass on its option for the therapeutic cancer vaccine TG4010. But the CEO says he's laying the groundwork for a late-stage study, confident that he can find another partner.
Novartis' generic of Advair in Europe is already a thorn in GlaxoSmithKline's side when it comes to sales of the declining blockbuster. Now, it says, another of its lung drugs has turned out positive study data that show its non-inferiority to Glaxo's top seller in COPD, and with its more convenient dosing regimen, it could prompt patients on Advair to make the switch.
After Tuesday's precedent-setting deal announcement, today's earnings release from Novartis had to be an anticlimax. And it was: The results were described using unexciting words like "solid" and "flat" and "nice" and "largely in line."
GlaxoSmithKline hasn't spelled out exactly how its big deal with Novartis will impact individual workers. But the rumor mill has it that more than 100 investigators in cancer R&D in Collegeville, PA, are about to become Novartis workers.